Page 96 - Genentech News Today

“The Future of Healthcare 2023 – The Surgeons General Roundtable” will be held at Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) and stream live on YouTube from 9:30-11:00 am.

In the aftermath of Amgen v. Sanofi, courts continue to invalidate genus claims for lacking enablement. Baxalta Incorporated v. Genentech Inc.2 shows that it is nearly impossible to...

"Chronic Spontaneous Urticaria Market"DelveInsight's ‘Chronic Spontaneous Urticaria Market Insight, Epidemiology and Market Forecast—2032' report deliver an in-depth understanding of the Chronic Spontaneous Urticaria,

DelveInsight's Graft Versus Host Disease Market...

The feds should bolster sustainable commuting modes and transportation demand management strategies.

EpiSwitch Prostate Screening is designed to run alongside a standard PSA test PSE boosts PSA predictive accuracy from 55% to 94%1 for determining the presence or absence of prostate...

/PRNewswire/ -- Emtrain, an eLearning and analytics technology company that develops and measures ethics, respect and inclusion in the workplace, today...

Women who continue to receive screening mammograms for breast cancer beyond age 70 face a considerable risk for overdiagnosis, which increases with age, new research suggests.

This disease can, at the very least, help researchers to “identify” the floodgates to definitive tests and therapies for complex psychological and neurological diseases, expert says.

In Baxalta Incorporated v. Genentech, Inc., 2022-1461, the Federal Circuit affirmed the district court’s decision granting Genentech’s motion for summary judgment that claims 1-4, 9,...